

## D-Mannitol Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

### [ Product Information ]

**Name:** D-Mannitol

**Catalog No.:** CFN90046

**Cas No.:** 69-65-8


**Purity:** >=98%

**M.F:** C<sub>6</sub>H<sub>14</sub>O<sub>6</sub>

**M.W:** 182.17

**Physical Description:** Powder

**Synonyms:** 1,2,3,4,5,6-Hexanehexol; Cordycepic acid;Hexanehexol;Hexanhexol.



### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Diagnostic markers;
6. Others.

### [ Source ]

The herbs of *Peucedanum harry-smithii* var. *subglabrum*.

### [ Biological Activity or Inhibitors ]

D-mannitol, a specific hydroxyl free radical scavenger, can reduce the developmental toxicity of hydroxyurea in rabbits.<sup>[1]</sup>

*A. fumigatus* can produce and release sufficient D-mannitol in the tissues of infected animals to raise serum D-mannitol levels, thus, D-mannitol is a potential diagnostic marker for aspergillosis.<sup>[2]</sup>

D-Mannitol has thermal properties, it could be as a Phase Change Material (PCM) for latent heat storage system.<sup>[3]</sup>

D-mannitol has neuroprotectant effect in reducing the sensory neurological disturbances seen in ciguatera poisoning, it does not act purely as an osmotic agent to reduce swelling of nerves, but involves a more complex action dependent on the Na(v) channel subtype, possibly to alter or reduce toxin association.<sup>[4]</sup>

### **[ Solvent ]**

Pyridine, Methanol, Ethanol, etc.

### **[ HPLC Method ]<sup>[5]</sup>**

HPLC-ELSD

Mobile phase: H<sub>2</sub>O;

Flow rate: 0.6 ml/min;

Column temperature: 65 °C;

Drift tube temperature: 110 °C;

Flow rate of gas : 3.0L/min;

Carrier gas: N<sub>2</sub>.

### **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

### **[ References ]**

- [1] Desesso J M, Scialli A R, Goeringer G C. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 1994, 49(4):248-59.
- [2] Wong B, Brauer K L, Tsai R R, *et al. J.Infect. Dis.*, 1989, 160(1):95-103.
- [3] Kumaresan G, Velraj R, Iniyar S.*J. Appl. Sci.*, 2011, 11(16):3044-8.
- [4] Birinyi-Strachan L C, Davies M J, Lewis R J, *et al. Neuropharmacology*, 2005, 49(5):669-86.
- [5] Han D, Chen X, Gao J, *et al. China Pharmacist*, 2014, 17(1):67-9.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)